MyoKardia (MYOK) – FDA
-
MyoKardia (MYOK) Reports First Patient Dosing in Phase 2 Clinical Trial of Danicamtiv in Genetic Dilated Cardiomyopathy
-
MyoKardia (MYOK) Announces Results from Phase 3 EXPLORER-HCM Clinical Trial of Mavacamten for Treatment of Obstructive Hypertrophic Cardiomyopathy
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Back to MYOK Stock Lookup